

Tuberculosis profile: Estonia

Population 2019: 1.3 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	170 (140-200)	13 (11-15)
HIV-positive TB incidence	19 (11-30)	1.5 (0.83-2.3)
MDR/RR-TB incidence**	39 (24-58)	3 (1.8-4.4)
HIV-negative TB mortality	13 (13-13)	0.98 (0.97-0.99)
HIV-positive TB mortality	3 (2-5)	0.23 (0.12-0.39)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	17% (10-26)
Previously treated cases	52% (30-74)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	10% (8-11)

TB case notifications, 2019

Total new and relapse	147
- % tested with rapid diagnostics at time of diagnosis	90%
- % with known HIV status	95%
- % pulmonary	93%
- % bacteriologically confirmed ^	91%
- % children aged 0-14 years	1%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	32%
- % men	67%
Total cases notified	150

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	16	12%
- on antiretroviral therapy	14	88%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	100%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB ^^	29
Patients started on treatment - MDR/RR-TB ^^	28
Laboratory-confirmed cases - XDR-TB ^^	4
Patients started on treatment - XDR-TB ^^	4
MDR/RR-TB cases tested for resistance to any fluoroquinolone	25

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	83%	115
Previously treated cases, excluding relapse, registered in 2018		0
HIV-positive TB cases registered in 2018	88%	8
MDR/RR-TB cases started on second-line treatment in 2017	88%	25
XDR-TB cases started on second-line treatment in 2017	60%	10

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	
---	--



Treatment success rate



Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 100% (100-100)

TB financing

National TB budget, 2020 (US\$ millions)	1
- Funding source, domestic	100%
- Funding source, international	
- unfunded	0%

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-21 by the World Health Organization (<https://www.who.int/tb/data/>)